These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 34652116)

  • 21. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics.
    Csernansky JG; Schuchart EK
    CNS Drugs; 2002; 16(7):473-84. PubMed ID: 12056922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of Antipsychotic Drugs for 24-Month Maintenance Treatment in First-Episode Schizophrenia: Evidence From a Community-Based "Real-World" Study.
    Zhang C; Chen MJ; Wu GJ; Wang ZW; Rao SZ; Zhang Y; Yi ZH; Yang WM; Gao KM; Song LS
    J Clin Psychiatry; 2016 Nov; 77(11):e1460-e1466. PubMed ID: 28076667
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence and Impact of Relapse in Patients With Schizophrenia.
    Lauriello J
    J Clin Psychiatry; 2020 Mar; 81(2):. PubMed ID: 32237296
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Success of new treatments for schizophrenics, as shown by the example of modern antipsychotic drugs].
    Lambert M; Naber D; Perro C; Moritz S; Krausz M
    Psychiatr Prax; 1999 Apr; 26 Suppl 1():S30-5. PubMed ID: 10407922
    [No Abstract]   [Full Text] [Related]  

  • 25. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia.
    Gaebel W; Riesbeck M; Wölwer W; Klimke A; Eickhoff M; von Wilmsdorff M; Jockers-Scherübl MC; Kühn KU; Lemke M; Bechdolf A; Bender S; Degner D; Schlösser R; Schmidt LG; Schmitt A; Jäger M; Buchkremer G; Falkai P; Klingberg S; Köpcke W; Maier W; Häfner H; Ohmann C; Salize HJ; Schneider F; Möller HJ;
    J Clin Psychiatry; 2007 Nov; 68(11):1763-74. PubMed ID: 18052570
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia.
    Emsley R; Chiliza B; Asmal L; du Plessis S; Phahladira L; van Niekerk E; van Rensburg SJ; Harvey BH
    Schizophr Res; 2014 Sep; 158(1-3):230-5. PubMed ID: 24996507
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is the ongoing use of placebo in relapse-prevention clinical trials in schizophrenia justified?
    Emsley R; Fleischhacker WW
    Schizophr Res; 2013 Nov; 150(2-3):427-33. PubMed ID: 24094881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relapse prevention in patients with schizophrenia.
    Kane JM
    J Clin Psychiatry; 2008 Apr; 69(4):e11. PubMed ID: 18507484
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Novel Antipsychotic Drug Cariprazine and Cognition Enhancing Drugs: Indications for their Use as the Add-on Therapy in Schizophrenia.
    Werner FM; Coveñas R
    Curr Pharm Des; 2021; 27(39):4033-4038. PubMed ID: 33302854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimizing pharmacotherapy to maximize outcome in schizophrenia.
    Fusion Medical Education LLC
    J Clin Psychiatry; 2005 Jan; 66(1):122-33. PubMed ID: 15669898
    [No Abstract]   [Full Text] [Related]  

  • 31. Prospective 6-year trial with clozapine: negative symptoms in outpatients with schizophrenia improve despite intermittent positive symptoms.
    Gaertner I; Gaertner HJ; Vonthein R; Dietz K
    J Clin Psychopharmacol; 2002 Aug; 22(4):437-8. PubMed ID: 12172348
    [No Abstract]   [Full Text] [Related]  

  • 32. Antipsychotic treatment in the maintenance phase of schizophrenia: An updated systematic review of the guidelines and algorithms.
    Shimomura Y; Kikuchi Y; Suzuki T; Uchida H; Mimura M; Takeuchi H
    Schizophr Res; 2020 Jan; 215():8-16. PubMed ID: 31784340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of placebo in schizophrenia relapse prevention studies: scientific or ethical debate?
    Ćurković M; Borovečki A
    Acta Psychiatr Scand; 2019 Oct; 140(4):386-387. PubMed ID: 31407323
    [No Abstract]   [Full Text] [Related]  

  • 34. Impact of atypical antipsychotics on quality of life in patients with schizophrenia.
    Awad AG; Voruganti LN
    CNS Drugs; 2004; 18(13):877-93. PubMed ID: 15521791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cognitive effects of antipsychotics in schizophrenia and relationship to quality of life.
    Kaiser W
    Br J Psychiatry; 2000 Jan; 176():92-3. PubMed ID: 10789338
    [No Abstract]   [Full Text] [Related]  

  • 36. Relapse prevention in schizophrenia.
    Jauhar S; Laws K; Fusar-Poli P; McKenna P
    Lancet Psychiatry; 2022 Apr; 9(4):e13. PubMed ID: 35305747
    [No Abstract]   [Full Text] [Related]  

  • 37. Treating depression in schizophrenia.
    Lund BC; Perry PJ; Miller DD
    Am J Psychiatry; 2001 Sep; 158(9):1528-9. PubMed ID: 11532750
    [No Abstract]   [Full Text] [Related]  

  • 38. [Pharmacotherapy for schizophrenia].
    Fleischhacker WW; Hummer W
    Nervenarzt; 2006 Nov; 77 Suppl 2():S77-97; S98. PubMed ID: 17082927
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of antipsychotic dose reduction.
    Uchida H; Suzuki T; Takeuchi H; Mamo DC
    Am J Psychiatry; 2010 Aug; 167(8):994; author reply 994-5. PubMed ID: 20693469
    [No Abstract]   [Full Text] [Related]  

  • 40. Digital aids for relapse prevention in schizophrenia.
    Furukawa TA; Bighelli I
    Lancet Psychiatry; 2022 Jun; 9(6):424-425. PubMed ID: 35569494
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.